Collectively, our observations indicate that CDK8/19 inhibitors, including those currently in clinical trials for the treatment of various cancers, may prove useful for therapies to eliminate latently infected cells by suppressing HIV-1 expression. This evidence concerns the gene CDK8 and cancer.